DB
RNA

Danske Bank’s Atrium Therapeutics RNA Stock Holding History

Danske Bank’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282 Hold
21
– – ﹤0.01% 1021
2026
Q1 		$280 Buy
+21
New +$295 ﹤0.01% 1030

Other funds holding RNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $144M AUM 26.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return
SC
Slotnik Capital Dallas, Texas $387M AUM 106.2% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
CDMG
Creek Drive Management Group San Francisco, California $206M AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Danske Bank's RNA Position: Q2 2026 in Review

Danske Bank held its Atrium Therapeutics (RNA) position steady in Q2 2026 at 21 shares worth $282. The position accounts for ﹤0.01% of the portfolio, ranked #1021.

Danske Bank first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Danske Bank held 21 shares of Atrium Therapeutics worth $282 as of Q2 2026.
  • Danske Bank left its Atrium Therapeutics share count unchanged in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1021 holding.
  • Danske Bank first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.